Multipotent stem cells in cardiac regenerative therapy.
The potential for stem cells to ameliorate or cure heart diseases has galvanized a cadre of cardiovascular translational and clinical scientists to take a 'first-in-man' approach using autologous stem cells from a variety of tissues. However, recent clinical trial data show that when these cells are given by intracoronary infusion or direct myocardial injection, limited improvement in heart function occurs with no evidence of cardiomyogenesis. These studies illustrate the great need to understand the logic of cell-lineage commitment and the principles of cardiac differentiation. Recent identification of stem/progenitor cells of embryological origin with intrinsic competence to differentiate into multiple lineages within the heart offers new possibilities for cardiac regeneration. When combined with developments in nuclear reprogramming and provided that tumor risks and other challenges of embryonic cell transplantation can be overcome, the prospect of achieving autologous, cardiomyogenic, stem cell-based therapy may be within reach.
Karra
Ravi
R
Brigham and Women's Hospital, Department of Medicine, 75 Francis Street, Boston, MA 02115, USA. rkarra@partners.org
Wu
Sean M
SM
D000328:Adult; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D002986:Clinical Trials as Topic; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006321:Heart / Q000502:physiology*; D006801:Humans; D039902:Multipotent Stem Cells / Q000166:cytology*; D012038:Regeneration
D016179:Granulocyte Colony-Stimulating Factor